GALDERMA
28.3.2022 15:12:06 CEST | Business Wire | Press release
Galderma will present a range of new scientific data on its portfolio on their hyaluronic acid dermal filler range, their first liquid neuromodulator and their original collagen biostimulator at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place in Monaco and virtually from 31 March to 2 April 2022.
Dr Philippe Kestemont will present an overview of clinical data for Alluzience®, Galderma’s recently approved and Europe’s first ready-to-use liquid neuromodulator for the treatment of moderate to severe glabellar (frown) lines.1
Pooled data from two Phase III studies (NCT02353871 and NCT02493946) show that Alluzience® successfully improved glabellar lines regardless of severity with rapid onset and results lasting up to 6 months.2,3 Improvements in GL severity, satisfaction and psychological wellbeing were also consistent over several cycles of treatment with Alluzience®.2,3
The latest long-lasting efficacy and safety results will also be presented on the new formulation of Sculptra®, the original and only poly-L-lactic acid (PLLA) approved by the FDA. The new constitution means it can be reconstituted to 5ml or 8ml, used immediately and an optional 1mL of lidocaine can be added for patient comfort. The open-label extension study evaluating the new formulation of 8mL showed Sculptra® was well tolerated and had a long-lasting duration of effect, with subject satisfaction up to 96 weeks.4
“We are proud to sponsor the Aesthetics & Anti-Aging Medicine World Congress 2022 and we look forward to engaging with the aesthetics community, both in person in Monaco and virtually.
At Galderma, we believe in the benefits of delivering individualized aesthetics results. We are excited to host a symposium to bring this vision to the aesthetics community and share new data with a series of posters in our drive for innovation across our aesthetics portfolio.”
– Flemming Ørnskov, MD, MPH, Chief Executive Officer, Galderma
Galderma will also present data demonstrating the effectiveness and high patient satisfaction in patients treated with hyaluronic acid fillers. Results from Dr Andreas Nikolis’ CHEEKY post-market study evaluated treatment with Restylane® Lyft™ for those needing a projection effect and Restylane® Volyme™ for a contouring/volumizing effect.5
In addition, Dr Steven Dayan will detail positive results from a post-marketing study evaluating facial harmony and patient satisfaction after treatment with Restylane® Defyne™, a flexible hyaluronic acid filler, using a stepwise treatment approach.6
Finally, at AMWC, Galderma will be hosting a symposium that has been developed with some of the world’s most talented aesthetic physicians. Focusing on ‘A New Patient Centric Approach to turn your AART™ into a HIT™, the Galderma symposium will focus on how to use AART™ – Anatomy, Assessment, Regimen and Therapy – to deliver a Holistic Individualized Treatment (HIT) for each patient.
Moderated by Dr Andreas Nikolis (Canada), the symposium will feature interactive sessions with Sebastian Cotofana (US), Kay Durairaj (USA), Christoph Martschin (Sweden), Marcus Morais (Brazil) and Frank Rosengaus (Mexico), as well as live injections and a panel assessment.
The complete list of the new clinical data that Galderma and independent researchers will present is below:
Treatment |
Poster |
Number |
Alluzience® |
Ready-to-use liquid abobotulinumtoxinA for treatment of glabellar lines: An overview of available clinical data |
#3735 |
Sculptra® |
An open-label extension study to evaluate safety and effectiveness of a biostimulatory poly-L-lactic acid injectable implant after changes in reconstitution and injection procedure |
#3802 |
Restylane® Lyft™ Restylane® Volyme™ |
The CHEEKY Study: effectiveness of cheek treatment with hyaluronic acid fillers HA-VOL and HA-LYF |
#3719 |
Restylane® Defyne™ |
A randomized, post-marketing study to evaluate facial harmony and subject satisfaction after treatment with HA-DEF using a stepwise treatment approach |
#3730 |
For more information, the AMWC 2022 program is available here .
About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine.
Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com .
About Alluzience® (liquid botulinum toxin type A)
Alluzience® (liquid botulinum toxin type A) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe. Alluzience® should only be administered by a physician with appropriate qualifications and expertise in this treatment using the required equipment.1
Dosing and treatment intervals depend on assessment of the individual patient’s response.1
The treatment interval should be no more frequent than every three months.1
For more information, please see the Summary of Product Characteristics.1
Alluzience® is a product under license from Ipsen. Alluzience® is a registered trademark of Ipsen. Galderma has an exclusive license from Ipsen to develop, promote and distribute Alluzience® in the approved indication in Europe (excluding Czech Republic, Slovakia, Greece, Lithuania, Estonia, Latvia, Hungary).
About Sculptra®:
SCULPTRA® works to stimulate the skin’s own collagen production7
and is suitable for increasing the volume of depressed areas, particularly to correct skin depressions such as skin creases, wrinkles, folds and scars, and for signs of skin aging.8
SCULPTRA is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).8
SCULPTRA® is an injectable biostimulator containing microparticles of poly-L-lactic acid (PLLA) which gradually revitalizes the skin’s structural foundation, providing natural-looking, long-term results for up to 25 months.7,9 SCULPTRA was first approved in 1999 in Europe and it is currently available in more than 40 countries globally.
About Galderma’s Restylane portfolio
RESTYLANE is the original non-animal stabilized hyaluronic acid filler with over 25 years of achievement and over 50 million treatments worldwide.10
NASHA™ and OBT™ technologies make RESTYLANE the world’s most diverse range of fillers to deliver truly individualized results.11.12
The RESTYLANE portfolio of products includes RESTYLANE, RESTYLANE LYFT, RESTYLANE KYSSE, RESTYLANE VOLYME, RESTYLANE DEFYNE, RESTYLANE REFYNE, RESTYLANE EYELIGHT and RESTYLANE SKINBOOSTERS.
References:
- Summary of Product Characteristics, 10 June 2021.
- Ascher et al. Aesthet Surg J 2020;40:93-104.
- Kestemont et al. Aesthet Surg J 2021;Sep 2;sjab329.
- Prather et al. Poster #3802 to be presented at AMWC 2022.
- Nikolis A., Poster #3719 to be presented at AMWC 2022.
- Dayan S., Poster #3730 to be presented at AMWC 2022.
- Bohnert K et al. Plast Reconstr Surg 2019;127(4):1684–92.
- Sculptra IFU. 2018.
- Brown SA et al. Plast Reconstr Surg 2011;127(4):1684–92.
- Data on file (MA-39680).
- Data on file (MA-33939).
- Öhrlund A., Poster presented at AMWC 2019.
Prescribing information, trademarks and registration status may vary depending on local approval in each country. Always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC)
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005511/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
